Literature DB >> 7639014

Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles.

E S Cahill1, D T O'Hagan, L Illum, A Barnard, K H Mills, K Redhead.   

Abstract

The intranasal (i.n.) immunization of mice with Bordetella pertussis filamentous haemagglutinin (FHA) either as a solution or incorporated in biodegradable microparticles induced very similar immune responses. Both resulted in strong systemic IgG responses to FHA and good levels of anti-FHA IgG and IgA in the lungs of immunized mice. In comparison, the intraperitoneal (i.p.) immunization of mice with FHA, as a solution, engendered anti-FHA antibody responses which were stronger for serum IgG, similar for lung IgG and lower for lung IgA. The anti-FHA antibody levels, as measured by immunosorbent assay, were shown to correlate with their functional activity in the blocking of B. pertussis adhesion to HeLa tissue-culture cells. All three forms of immunization appeared to stimulate T-cell responses as assessed by in vitro antigen-specific spleen cell proliferation and IL-2 secretion indicative of a Th1 type response, however, cells from i.p. immunized mice only secreted low levels of IL-5. All three methods of FHA immunization provided mice with significant protection against subsequent aerosol challenge with virulent B. pertussis. Mice which had been immunized intra-nasally eliminated the bacteria from their lungs slightly more rapidly than i.p. immunized mice, demonstrating the efficacy of intranasal administration of FHA in solution and in the more practical biodegradable microparticle form.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7639014     DOI: 10.1016/0264-410x(94)00008-b

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

1.  Maternal immunity provides protection against pertussis in newborn piglets.

Authors:  Shokrollah Elahi; Rachelle M Buchanan; Lorne A Babiuk; Volker Gerdts
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

Review 2.  Recent advances in vaccine adjuvants.

Authors:  Manmohan Singh; Derek T O'Hagan
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

3.  Fusion expression and immunogenicity of Bordetella pertussis PTS1-FHA protein: implications for the vaccine development.

Authors:  Zhang Jinyong; Zhang Xiaoli; Zhang Weijun; Guo Ying; Guo Gang; Mao Xuhu; Zou Quanming
Journal:  Mol Biol Rep       Date:  2010-09-28       Impact factor: 2.316

4.  Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens.

Authors:  A Bacon; J Makin; P J Sizer; I Jabbal-Gill; M Hinchcliffe; L Illum; S Chatfield; M Roberts
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

5.  Bordetella pertussis proteins dominating the major histocompatibility complex class II-presented epitope repertoire in human monocyte-derived dendritic cells.

Authors:  Rachel M Stenger; Hugo D Meiring; Betsy Kuipers; Martien Poelen; Jacqueline A M van Gaans-van den Brink; Claire J P Boog; Ad P J M de Jong; Cécile A C M van Els
Journal:  Clin Vaccine Immunol       Date:  2014-03-05

6.  Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine.

Authors:  F Zepp; M Knuf; P Habermehl; J H Schmitt; C Rebsch; P Schmidtke; R Clemens; M Slaoui
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

7.  Th1/Th2 cell dichotomy in acquired immunity to Bordetella pertussis: variables in the in vivo priming and in vitro cytokine detection techniques affect the classification of T-cell subsets as Th1, Th2 or Th0.

Authors:  A Barnard; B P Mahon; J Watkins; K Redhead; K H Mills
Journal:  Immunology       Date:  1996-03       Impact factor: 7.397

8.  Highly attenuated Bordetella pertussis strain BPZE1 as a potential live vehicle for delivery of heterologous vaccine candidates.

Authors:  Si Ying Ho; Shi Qian Chua; Damian G W Foo; Camille Locht; Vincent T Chow; Chit Laa Poh; Sylvie Alonso
Journal:  Infect Immun       Date:  2007-10-22       Impact factor: 3.441

9.  A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice.

Authors:  Ciaran M Skerry; Joseph P Cassidy; Karen English; Pascal Feunou-Feunou; Camille Locht; Bernard P Mahon
Journal:  Clin Vaccine Immunol       Date:  2009-07-22

10.  Construction and characterization of single-chain variable fragment antibodies directed against the Bordetella pertussis surface adhesins filamentous hemagglutinin and pertactin.

Authors:  Ahmad H Hussein; Elisabeth M Davis; Scott A Halperin; Song F Lee
Journal:  Infect Immun       Date:  2007-08-27       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.